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Abstract 
Background: Patients in the intensive care unit (ICU) are more prone to drug–drug interactions (DDIs). The software 
and charts that indicate all interactions may not be proper for clinical usage. This study aimed to identify the main 
drug classes associated with clinically significant DDIs in cardiothoracic ICU and categorize DDIs to make cardiotho-
racic intensivists aware of safe medication usage.
Methods: This prospective study was conducted over 6 months in a cardiothoracic ICU of a university-affiliated 
teaching hospital. The presence of potential drug–drug interactions (pDDIs) was assessed by a clinical pharmacolo-
gist using Lexi-Interact database. Clinically significant pDDIs were defined according to severity and reliability rating. 
Interacting drug classes, mechanisms, and recommendations were identified for each interaction.
Results: From 1780 administered drugs, 496 lead to major (D) and contraindicated (X) interactions. Nine drug 
classes were responsible for D and/or X interactions with excellent (E) and/or good (G) reliability. Anti-infective agents 
(45.87 %) were the main drug classes that caused clinically significant pDDIs followed by central nervous system drugs 
(14.67 %). Azole antifungals as the most interacting antimicrobial agents precipitated metabolism inhibition of CYP3A 
substrates.
Conclusions: Clinically significant pDDIs as potential patient safety risks were prevalent in critically ill patients. The 
findings from current study help to improve knowledge and awareness of clinicians in this area and minimize adverse 
events due to pDDIs.
© 2015 Baniasadi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Drug–drug interactions (DDIs) are a growing concern 
in all clinical settings, particularly intensive care units 
(ICUs) [1]. ICU-admitted patients are at an increased 
risk of DDIs due to the complexity of pharmacotherapy, 
large number of medications, disease severity, and organ 
failure [2–5]. DDIs are common causes of adverse drug 
events that may affect patient health; therefore, the 
identification and prevention of potential drug–drug 
interactions (pDDIs) could improve patient safety [6]. 
Since it would be impossible for any physician to remem-
ber all pDDIs, improving the knowledge of clinical prac-
titioners in terms of clinically important DDIs could 
reduce the risk of serious adverse outcomes. Applying 
DDI software and employing clinical pharmacists to 
detect and prevent DDIs have improved patient safety in 
advanced countries [1, 7], while physicians in developing 
countries still identify DDIs based on their own experi-
ences [8, 9].
Previous studies regarding pDDIs have focused on 
frequency, type, mechanisms, severity, drug combina-
tions, management and related outcomes in ICU set-
tings [1, 10–14], but important drug classes involved in 
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well-documented and severe pDDIs in cardiothoracic 
ICU have not yet been reported. Therefore, the current 
study aimed to highlight the main drug classes associated 
with clinically important DDIs. The results of this study 
could increase knowledge among intensivists (especially 
cardiothoracic intensivists) in the context of DDI preven-
tion and safe medication usage.
Methods
Study design and protocol
This cross-sectional study was conducted at Masih 
Daneshvari Hospital, a university-affiliated hospital for 
lung diseases, over a 6-month period. The study proto-
col was approved by the hospital’s ethical review board. 
Data related to the pharmacotherapy of the subjects were 
assessed 48  h after admission to an 8-bed surgical car-
diothoracic ICU by a clinical pharmacologist using Lexi-
Interact database, a complete drug and herbal interaction 
analysis program. The software identifies interacting 
drugs, mechanisms, severity, reliability (documentation) 
rating (E = excellent, G = good, F = fair), potential out-
comes, and clinical management. According to sever-
ity, the interactions are categorized into five categories: 
A (unknown), B (minor), C (moderate), D (major), and 
X (contraindicated) [15]. Drugs involved in pDDIs and 
subjects’ diagnoses were classified according to AHFS 
Drug Information [16] and International Classifica-
tion of Diseases (ICD10), respectively [17]. At the time 
of admission, any home medication, herbal medication, 
and nutritional supplements were stopped according to 
the ICU policy. Hydro-electrolytic components, insulin, 
water-soluble vitamins, and topical drugs were excluded 
from further analysis. Physicians were notified of interac-
tions that might lead to alterations in drug therapy.
Data analysis
Data were analyzed using descriptive statistics from the 
SPSS software v.22.0 for Windows (SPSS, Chicago, IL). 
The median, range, and percentage were applied to pre-
sent the results where appropriate. The interacting drug 
classes, significance, reliability, and clinical management 
of the interactions were recorded in a database. Interac-
tions with a severity rating of D and/or X and a reliability 
rating of E and/or G were considered clinically important 
pDDIs for more analysis.
Results
Overall, 195 prescriptions were evaluated over the 
6-month study period. Table  1 shows the demographic 
and clinical characteristics of the subjects. The average 
length of stay in ICU was 5 days. Total administered and 
interacting medications (D and X interactions with any 
documentation rating) were 1780 and 496, respectively 
(Table  2). D and/or X interactions were identified in 
37.94 % (74) of the prescriptions. Of the 248 pDDIs with a 
severity rating of D and/or X, 157 were unique drug pairs 
(a specific combination of interacting medication that is 
counted one time). The drug classes and specific medica-
tions involved in D and/or X interactions are shown in 
Table 3. The drug pairs causing D and/or X interactions 
with E and/or G reliability are displayed in Table 4.
Discussion
The present study evaluated clinically important pDDIs 
in terms of drug classes, mechanisms, and recommenda-
tions in the cardiothoracic ICU. Scientifically, important 
measures to decrease the risk of DDIs are computerized 
prescribing, pharmacotherapy monitoring, and phar-
macist participation in the multidisciplinary team [18]. 
Where these services are not available (e.g., due to budget 
shortages), continued education and expert studies on 
pDDIs could improve patient safety. Software that iden-
tifies a large number of DDIs with any rating of severity 
and reliability could result in a lack of attention given to 
the warnings [19]. Categorizing DDIs by drug classes and 
highlighting more severe and reliable interactions may 
increase the tendency of clinicians to prevent clinically 
significant DDIs.
Results of the current study revealed that anti-infective, 
central nervous system (CNS), and cardiovascular agents 
were the main drug classes involved in D and X pDDIs. 
Antimicrobials were the most administered medications 
in the studied setting and were responsible for a high 
number of pDDIs. Anti-infective agents are commonly 
used in the ICU and are associated with clinically signifi-
cant interactions [20]. Antithrombotic agents and cardio-
vascular drugs are usually reported as the most common 
interacting drug groups in ICU settings [1, 10–12]. Dif-
ferent results may be related to the inclusion of moder-
ate and/or not well-documented pDDIs in other studies. 
These authors’ previous study also showed that antibi-
otics were the most commonly implicated drug class 
for adverse drug reactions [21]. Overestimated usage of 
antibiotics is an important issue in developing countries 
where the use of antibiotics requires close monitoring to 
ensure effective treatment and, ultimately, cost reduction 
[22].
A wide range of different consequences could be 
predicted according to DDIs mechanisms. The altered 
gastrointestinal (GI) absorption of antibiotics and the 
inhibition/induction of drug metabolizer enzymes are 
the mechanisms most often associated with antimi-
crobial interactions [20, 23]. The inhibition of metab-
olism by azole antifungal agents (most interacting 
drugs in the current study) may lead to increased tac-
rolimus and cyclosporine concentrations in transplant 
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patients and the increased toxicity of these medications 
[24]. On the other hand, metabolism induction usu-
ally results in decreased clinical efficacy of other drugs 
instead of adverse effects. Quinolones and macrolides 
(with torsadogenic potential) may interact synergically 
with other medications and result in QTc prolonga-
tion and torsades de pointes [25]. It was also found that 
these mechanisms play the main role in anti-infective 
interactions that could be managed by adjusting drug 
administration time, and dosage, or using an alterna-
tive medication [23, 25].
CNS drugs were 20.50 and 19.95  % of administered 
medications and interacting drugs, respectively. These 
medications are frequently used to control seizures, 
pain, and anxiety and to treat delirium, depression, and 
psychotic symptoms in ICU settings [26]. A conducted 
study in a mixed ICU showed that 40  % of the pDDIs 
were associated to drugs acting on CNS [27]. In the cur-
rent study, 14.67 % of D and/or X pDDIs with reliability 
ratings of E and/or G were related to these agents as a 
precipitant drug. Carbamazepine was the most frequent 
CNS drug that interacted with CYP3A substrates (such 
Table 1 Demographic and clinical characteristics of the patients
Characteristics
Number of patients (n) 184
Age [median (range)] 48 (3–85)
Gender (male/female) 110/74
Number of prescriptions (n) 195
Number of prescriptions including:
 1–8 drugs (n) 110
 9–17 drugs (n) 71
 18–25 drugs (n) 14
Diagnoses classification (n)
 Certain infectious and parasitic diseases 7
 Neoplasms 43
 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism 1
 Diseases of the circulatory system 32
 Diseases of the respiratory system 68
 Diseases of the digestive system 6
 Congenital malformations, deformations and chromosomal abnormalities 6
 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 1
 Injury, poisoning and certain other consequences of external causes 4
 Factors influencing health status and contact with health services 16
Table 2 The number and percentages of total administered and interacting drugs in different drug classes
Drug classes Total administered  
drugs % (n)
D and/or X interacting  
drugs % (n)
D and/or X interacting precipitant 
drugs with E and/or G reliability % (n)
Anti-infective agents 22.35 % (398) 25.00 % (124) 45.87 % (50)
Central nervous system agents 20.50 % (365) 19.95 % (99) 14.67 % (16)
Cardiovascular drugs 19.21 % (342) 13.10 % (65) 5.50 % (6)
Gastrointestinal drugs 12.80 % (228) 6.65 % (33) 4.58 % (5)
Hormones and synthetic substitutes 6.68 % (119) 11.29 % (56) 2.75 % (3)
Respiratory tract agents 6.40 % (114) 3.22 % (16) –
Electrolytic, caloric, and water balance 5.33 % (95) 6.65 % (33) 10.09 (11)
Blood formation, coagulation, and thrombosis 2.07 % (37) 3.42 % (17) 3.67 % (4)
Autonomic drugs 2.02 % (36) 3.02 % (15) 9.17 % (10)
Miscellaneous therapeutic agents 2.02 % (36) 7.05 % (35) 3.66 % (4)
Vitamins 0.56 % (10) 0.60 % (3) –
Total 1780 496 109
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as phenytoin, clonazepam, and warfarin). Monitoring 
the therapeutic effects of object drugs and considering 
an alternative medication (if possible) are recommended 
as appropriate interventions [28]. In addition to metab-
olism, additive and antagonistic effects were the main 
mechanisms for CNS drug interactions in this study.
Electrolytic, caloric, and water balance agents, which 
include metal ions, accounted for 10.09  % of clinically 
important pDDIs. Metal ions form complexes with other 
medications, especially antimicrobial agents, and affect 
drug absorption. A reasonable recommendation is to 
administer oral medications at least 1–2  h before, and 
not within 4 h after, administering the metal ions [23].
In autonomic drug classes, the combination of neuro-
muscular blocking agents and corticosteroids may lead 
to further risk of prolonged muscle weakness, including 
neuropathy, myopathy, and/or paralysis. This has been 
observed most commonly in the ICU setting, particu-
larly in patients requiring high doses of intravenous ster-
oids [29]. It is recommended to monitor for new onset 
or worsening of adverse neuromuscular effects and to 
use a neuromuscular blocking drug only when absolutely 
necessary [30]. Corticosteroids were administered com-
monly for tracheal stenosis (15.2  %) and COPD (4.3  %) 
in the studied setting. After that, neoplasms (23.4 %) and 
transplants (8.7  %) were the most common indications 
for corticosteroid administrations.
Although “cardiovascular” and “blood formation, coag-
ulation, and thrombosis” agents accounted for 21.28  % 
of administered medications and 16.52  % of interacting 
drugs, only 9.17 % of well-documented D and/or X inter-
actions were related to these groups as precipitant drugs. 
As mentioned above, pDDIs were classified according to 
the object and precipitant drugs. In 18.35  % of pDDIs, 
the drugs belonging to these groups were object drugs. 
Documentation rating was considered to highlight clini-
cally important pDDIs. A high number of interactions 
caused by these drug classes were rated as fair docu-
mentation. Amiodarone (a CYP2D6 inhibitor) should be 
considered as a precipitant drug with a large number of 
interactions. Considering an alternative for one of the 
interacting agents and monitoring responses are usually 
recommended [31].
Proton pump inhibitors (PPIs) and histamine-2 recep-
tor antagonists (H2RAs) are routinely used for critically 
ill subjects who are at high risk for stress-related mucosal 
damage (SRMD) [32]. The pH-raising effect of these GI 
drugs may decrease absorption and the serum concentra-
tion of azole antifungal agents (itraconazole, voricona-
zole, and posaconazole). Use of the azoles oral solutions 
(instead of capsule) or administration of the azoles with 
an acidic beverage could minimize the significance of 
this interaction [33]. Variations in practices and medica-
tions between ICU settings may lead to different pDDIs 
patterns [1]. Proton pump inhibitors are administered in 
the currently studied setting to patients with a history of 
GI disorders, major surgeries, and anticoagulant usage. 
Although there is lack of firm evidence that PPI reduces 
Table 3 Drug classes, specific medications associated with D and/or X interactions, and the frequency of interactions
Drug classes (frequency of interactions) Specific medications (frequency of interactions)
Anti-infective agents (124) Itraconazole (24), Ciprofloxacin (17), Voriconazole (16), Rifampin (14), Clarithromycin (11), Erythro-
mycin (10), Dapsone (7), Co-trimoxazole (5), Levofloxacin (4), Posaconazole (4), Meropenem (3), 
Ofloxacin (3), Isoniazid (2), Pyrazinamide (1), Lamivudine (1), Valganciclovir (1), Caspofungin (1)
Central nervous system agents (99) Carbamazepine (20), Phenytoin (16), Fentanyl (11), Midazolam (10), Haloperidol (8), Valproic acid 
(5), Indomethacin (5), Quetiapine fumarate (4), Citalopram (4), Risperidone (2), Imipramine (2), 
Clonazepam (2), Methadone (2), Lorazepam (1), Chlorpromazine (1), Celecoxib (1), Diclofenac (1), 
Fluvoxamine (1), Alprazolam (1), Clomipramine (1), Carbidopa and Levodopa (1)
Cardiovascular drugs (65) Atorvastatin (19), Metoprolol (10), Losartan (6), Amiodarone (6), Amlodipine (4), Diltiazem (4), Cap-
topril (3), Sildenafil (2), Carvedilol (2), Furosemide (2), Digoxin (2), Propranolol (1), Dabigatran (1), 
Heparin (1), Enalapril (1), Gemfibrozil (1)
Hormones and synthetic substitutes (56) Dexamethasone (33), Prednisolone (9), Methylprednisolone (6), Levothyroxine (4), Hydrocortisone 
(3), Octreotide (1)
Miscellaneous therapeutic agents (35) Cyclosporine (15), Tacrolimus (10), Mycophenolate (6), Tamsulosin (3), ALLOPURINOL (1)
Electrolytic, caloric, and water balance (33) Calcium carbonate (16), Magnesium sulfate (5), Sodium polystyrene sulfate (4), Calcium gluconate 
(3), Sodium phosphate (2), Spironolactone (1), Zinc sulfate (1), Potassium chloride (1)
Gastrointestinal drugs (33) Pantoprazole (19), Granisetron (8), Ranitidine (3), Metoclopramide (1), Omeprazole (1), Aluminum, 
Magnesium hydroxide (1)
Blood formation, coagulation, and thrombosis (17) Warfarin (6), Clopidogrel (4), Ferrous sulfate (4), Acetylsalicylic acid (3)
Respiratory tract agents (16) Ipratropium (7), Formoterol (3), Fluticasone (3), Salbutamol (2), Theophylline (1)
Autonomic drugs (15) Atracurium (9), Tizanidine (2), Prazosin (2), Cisatracurium (1), Epinephrine (1)
Vitamins (3) Calcitriol (3)
Page 5 of 8Baniasadi et al. Ann. Intensive Care  (2015) 5:44 
Table 4 Drug classes, precipitant and object drugs, mechanisms and recommendations for clinically significant pDDIs
Drug classes Precipitant  
drugsa
Object drugsa Mechanisms Recommendations
Anti-infective 
agents
Itraconazole Tacrolimus Metabolism (inh) Monitor tacrolimus concentration
Diltiazem Metabolism (inh) Monitor diltiazem toxic effects
Digoxin Absorption Monitor digoxin concentration
Atorvastatin Metabolism (inh) Reduce dose, monitor toxic effects
Clarithromycin Metabolism (inh)b Monitor toxic effect of clarithromycin/itraconazole
Methylprednisolone Metabolism (inh) Reduce dose, monitor corticosteroid toxicity
Voriconazole Tacrolimus Metabolism (inh) Reduce dose, monitor tacrolimus concentration
Cyclosporine Metabolism (inh) Reduce dose, monitor cyclosporine concentration
Diltiazem Metabolism (inh) Monitor diltiazem toxic effects
Methylprednisolone Metabolism (inh) Reduce dose, monitor corticosteroid toxicity
Methadone Metabolism (inh) Monitor methadone toxic effects
Midazolam Metabolism (inh) Monitor midazolam toxic effects
Ciprofloxacin Theophylline Metabolism (inh) Reduce dose, monitor theophylline toxic effects
Erythromycin Additive Avoid combination
Formoterol Additive Avoid combination
Granisetron Additive Avoid combination
Voriconazole Additive Avoid combination
Rifampin Itraconazole Metabolism (ind/inh)b Avoid combination/monitor for clinical response to itraconazole
Clarithromycin Metabolism (ind/inh)b Monitor for clarithromycin therapeutic effects/rifampin toxic 
effects
Cyclosporine Metabolism (ind) Consider an alternative, monitor cyclosporine serum concentra-
tions
Midazolam Metabolism (ind) Monitor midazolam therapeutic effects
Dapsone Metabolism (ind) Monitor for dapsone therapeutic effects and methemoglobine-
mia
Erythromycin Amlodipine Metabolism (inh) Consider an alternative, monitor toxic effects
Carbamazepine Metabolism (inh) Consider an alternative, monitor toxic effects
Dexamethasone Metabolism (inh) Monitor corticosteroids toxic effects
Prednisolone Metabolism (inh) Monitor corticosteroids toxic effects
Posaconazole Midazolam Metabolism (inh) Consider an alternative, monitor toxic effects
Isoniazid Metoprolol Metabolism (inh) Consider an alternative, monitor response
Valganciclovir Lamivudine Additive Monitor hematologic toxicity




Carbamazepine Phenytoin Metabolism (ind)b Monitor for phenytoin/carbamazepine serum concentrations
Clonazepam Metabolism (ind) Consider an alternative
Warfarin Metabolism (ind) Monitor therapeutic effects
Citalopram Metabolism (ind/inh)b Monitor citalopram therapeutic effects/carbamazepine toxic 
effects
Fluvoxamine Metabolism (ind/inh)b Monitor fluvoxamine therapeutic effects/carbamazepine toxic 
effects
Imipramine Metoprolol Metabolism (inh) Consider an alternative, monitor response




Haloperidol Additive Avoid combination
Carbidopa and  
levodopa
Antagonistic Consider an alternative
Phenytoin Amlodipine Metabolism (ind/inh)b Monitor amlodipine therapeutic effects/phenytoin toxicity
Indomethacin Acetylsalicylic acid Additive Monitor bleeding, avoid regular use of indomethacin
Cyclosporine Additive Consider an alternative, monitor nephrotoxicity
Furosemide Antagonistic Monitor therapeutic effect
Valproic acid Lorazpam Metabolism (inh) Monitor lorazepam toxic effects
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GI bleeding compared with H2RA or placebo in ICU 
patients [34], an international survey of 97 units in 11 
countries showed that PPIs were the most common stress 
ulcer prophylaxis agent, used in 66  % of ICUs (64/97) 
[35]. Using oral PPIs instead of intravenous injection 
could be a useful strategy to prevent pDDIs.
In hormone and synthetic substitutes, an impor-
tant interaction occurred between dexamethasone and 
CYP3A substrates (clarithromycin and itraconazole). 
Dexamethasone as a strong CYP3A inducer may decrease 
the serum concentration and therapeutic effectiveness of 
these medications [36]. Alternative antimicrobial therapy 
(when possible) and monitoring patients closely for evi-
dence of diminished clinical response are important pre-
ventive measures.
Immunosuppressive drugs classified as miscellaneous 
therapeutic agents can lead to life-threatening pDDIs 
in transplant subjects. Cyclosporine has been shown to 
reduce the AUC of mycophenolic acid (MPA) by inhibit-
ing its glucuronide conjugate mycophenolic acid glucuro-
nide conjugate (MPAG) excretion into the bile. Changes 
in mycophenolate dosage may be required in cases of 
concurrent cyclosporine starting, stopping, or dose 
changing [37]. Studies have shown that the concurrent 
use of cyclosporine with atorvastatin can increase sys-
temic exposure to the statins and related toxicities such 
as myopathy and rhabdomyolysis. A statin that is less 
sensitive to this interaction (e.g., pravastatin or fluvasta-
tin) or an alternative type of LDL-lowering medication 
should be considered [37, 38].
Several limitations could be considered for the current 
study. Age is an important factor for DDIs prevalence, 
and a positive relationship has been found between age 
and the number of DDIs [9]. The median age of patients 
Table 4 continued
Drug classes Precipitant  
drugsa







Calcium carbonate Antagonistic Separate doses by 2 or more hours, monitor metabolic alkalosis
Zinc sulfate Ofloxacin Absorption Separate doses by 2 or more hours
Magnesium 
sulfate
Ciprofloxacin Absorption Separate doses by 2 or more hours
Calcium carbon-
ate
Isoniazid Absorption Separate doses by 2 or more hours
Levofloxacin Absorption Separate doses by 2 or more hours
Mycophenolate Absorption Separate doses by 2 or more hours
Autonomic 
drugs
Atracurium Methylprednisolone Additive Monitor neuromuscular adverse effects
Prednisolone Additive Monitor neuromuscular adverse effects
Dexamethasone Additive Monitor neuromuscular adverse effects
Hydrocortisone Additive Monitor neuromuscular adverse effects
Cisatracurium Prednisolone Additive Monitor neuromuscular adverse effects
Cardiovascular 
drugs
Amiodarone Digoxin Excretion Reduce digoxin dosage, monitor serum concentration
Metoprolol Metabolism (inh) Consider an alternative, monitor response
Gemfibrozil Atorvastatin Metabolism (inh) Avoid combination






Warfarin Additive Monitor bleeding
Ferrous sulfate Ofloxacin Absorption Separate doses by 4 or more hours
Levothyroxine Absorption Separate doses by 2 or more hours
Gastrointestinal 
drugs
Pantoprazole Itraconazole Absorption Administer itraconazole with an acidic beverage, monitor 
response





Dexamethasone Clarithromycin Metabolism (ind/inh)b Consider alternative antimicrobial therapy/monitor for dexa-
methasone toxic effects
Itraconazole Metabolism (ind) Avoid combination, monitor for therapeutic effects
Miscellaneous Cyclosporine Atorvastatin Metabolism (inh) Avoid combination
Mycophenolate Excretion Monitor mycophenolate dosing and response to therapy
inh Inhibition, ind induction
a The precipitant drug causes the interaction and the object drug is affected by the interaction
b Both medications act on each other
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in this study (48  years) was lower than that of western 
countries. Differences between the ICUs in developing 
and advanced countries could explain this discrepancy. 
For an appropriate interpretation and application of the 
ICU data, the diversity among countries including fund-
ing, laws, cultural values, and disease prevalence should 
be considered [39, 40]. In the current study, tracheal ste-
nosis and empyema were the most common respiratory 
system diseases that lead to ICU admissions. Therefore, 
several reasons (prevalence of diseases, culture, laws, and 
life expectancy) may play a role in the low median age of 
patients in the current study.
The second limitation is using one DDI database that 
could limit the number of pDDIs. Lexi-Interact is a com-
monly used resource providing detailed DDI information 
and was available in the studied hospital. This database 
with a documentation rating that is useful in recogniz-
ing well-documented interactions would limit clini-
cal repercussions. Using different software at the same 
time, however, could lead to more accurate results [41]. 
The setting of the current study, the cardiothoracic ICU 
of a pulmonary referral hospital, is another limitation. A 
list of drugs approved by hospital formulary committee 
is specific for an ICU setting. However, commonly used 
drugs in ICUs are usually considered in critical care drug 
handbooks and manuals [42, 43]. Therefore, reported 
interactions related to common drugs could be general-
ized to other ICUs. The interactions caused by specific 
medications prescribed in a specialized ICU could also 
be identified and prevented by similar studies.
Conclusions
Due to the high prevalence of pDDIs in the ICU set-
ting, the authors recommend more specialized studies 
on clinically significant pDDIs and continued education 
based on the results. Highlighting important drug classes 
and specific medications responsible for the interactions 
in different settings could increase the knowledge and 
awareness of clinicians to improve patient safety.
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